{"id":26462,"date":"2021-11-29T16:26:19","date_gmt":"2021-11-29T15:26:19","guid":{"rendered":"https:\/\/ellipse.prbb.org\/?p=26462"},"modified":"2021-11-29T16:26:10","modified_gmt":"2021-11-29T15:26:10","slug":"un-acord-estrategic-per-accelerar-el-desenvolupament-de-nous-farmacs","status":"publish","type":"post","link":"https:\/\/ellipse.prbb.org\/ca\/un-acord-estrategic-per-accelerar-el-desenvolupament-de-nous-farmacs\/","title":{"rendered":"Un acord estrat\u00e8gic per accelerar el desenvolupament de nous f\u00e0rmacs"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">El <a rel=\"noreferrer noopener\" href=\"http:\/\/www.crg.eu\/\" target=\"_blank\">Centre de Regulaci\u00f3 Gen\u00f2mica (CRG)<\/a> i <strong>l&#8217;empresa biotecnol\u00f2gica <a rel=\"noreferrer noopener\" href=\"https:\/\/www.chemotargets.com\/\" target=\"_blank\"><strong>Chemotargets<\/strong><\/a><\/strong> han arribat a <a rel=\"noreferrer noopener\" href=\"https:\/\/www.crg.eu\/en\/news\/chemotargets-and-crg-ally-accelerate-development-new-treatments#1\" target=\"_blank\">un acord de col\u00b7laboraci\u00f3<\/a> per facilitar i accelerar el proc\u00e9s de <strong>cerca de dianes terap\u00e8utiques i el posterior <a href=\"https:\/\/ellipse.prbb.org\/ca\/facilitar-el-disseny-de-farmacs-una-plataforma-per-estudiar-les-gpcrs\/\" target=\"_blank\" rel=\"noreferrer noopener\">desenvolupament de f\u00e0rmacs<\/a><\/strong>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Aquesta iniciativa uneix, d&#8217;una banda, l&#8217;experi\u00e8ncia del CRG en la identificaci\u00f3 de noves <strong>dianes terap\u00e8utiques per a malalties<\/strong> com el <a rel=\"noreferrer noopener\" href=\"https:\/\/ellipse.prbb.org\/ca\/potencial-via-per-evitar-la-resistencia-al-tractament-dun-dels-cancers-de-mama-mes-agressius\/\" target=\"_blank\">c\u00e0ncer<\/a>, la fibrosi, <a rel=\"noreferrer noopener\" href=\"https:\/\/ellipse.prbb.org\/ca\/maria-pia-cosma-crg-volem-mantenir-vius-els-ulls-dels-donants-durant-un-mes\/\" target=\"_blank\">malalties oculars<\/a>, malalties de la sang o malalties que provoquen inflamaci\u00f3; i per una altra, la <strong>tecnologia d&#8217;avantguarda<\/strong>, la <a rel=\"noreferrer noopener\" href=\"https:\/\/ellipse.prbb.org\/ca\/natalia-vilor-tejedor-crg-potenciant-la-diversitat-en-la-recerca-mes-gent-tindra-la-seguretat-per-contribuir-i-el-benefici-general-sera-major\/\" target=\"_blank\">computaci\u00f3 <\/a>i l&#8217;an\u00e0lisi de dades que ofereix Chemotargets &#8211; una spin off de l&#8217;<a rel=\"noreferrer noopener\" href=\"http:\/\/www.imim.es\/\" target=\"_blank\">Institut Hospital del Mar d\u2019Investigacions M\u00e8diques&nbsp;(IMIM)<\/a>, un altre dels centres del PRBB.<\/p>\n\n\n\n<div style=\"height:34px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\"><p>\u201cEl nou acord amb Chemotargets ser\u00e0 un impuls vital per a aprofitar el nostre coneixement per al benefici dels i les pacients que el necessiten\u201d<br><strong>Luis Serrano, director del CRG.<\/strong><\/p><\/blockquote>\n\n\n\n<div style=\"height:33px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p class=\"wp-block-paragraph\">Aix\u00ed, el primer projecte en com\u00fa se centrar\u00e0 en el <a href=\"https:\/\/ellipse.prbb.org\/ca\/estudiant-la-divisio-cel%c2%b7lular-en-granotes\/\" target=\"_blank\" rel=\"noreferrer noopener\">grup de Biologia Cel\u00b7lular i del Desenvolupament del CRG<\/a> liderat per <strong>Isabelle Vernos<\/strong>, en el qual s&#8217;estudiaran <a rel=\"noreferrer noopener\" href=\"https:\/\/ellipse.prbb.org\/ca\/descubreixen-possibles-dianes-terapeutiques-per-tractar-la-infertilitat-i-el-cancer\/\" target=\"_blank\"><strong>dianes terap\u00e8utiques relacionades amb la infertilitat i el c\u00e0ncer<\/strong><\/a>, processos relacionats amb la <a href=\"https:\/\/ellipse.prbb.org\/ca\/isabelle-vernos-crg-encara-em-sorpren-la-bellesa-duna-cel%c2%b7lula-en-divisio\/\" target=\"_blank\" rel=\"noreferrer noopener\">divisi\u00f3 cel\u00b7lular<\/a>, \u00e0rea d&#8217;experi\u00e8ncia del grup.<\/p>\n\n\n\n<div style=\"height:45px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p class=\"wp-block-paragraph\">Per a con\u00e8ixer m\u00e9s sobre el grup d&#8217;Isabelle Vernos i la recerca que duen a terme, no et perdis el seg\u00fcent v\u00eddeo realitzat amb motiu de les <a href=\"https:\/\/ellipse.prbb.org\/ca\/divulgacio-ciencia-i-reivindicacio-van-confluir-en-lopenprbb-la-semana-de-portes-obertes-del-prbb\/\" target=\"_blank\" rel=\"noreferrer noopener\"><strong>jornades de portes obertes del PRBB<\/strong><\/a>:<\/p>\n\n\n\n<div style=\"height:21px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<style>.embed-container { position: relative; padding-bottom: 56.25%; height: 0; overflow: hidden; max-width: 100%; } .embed-container iframe, .embed-container object, .embed-container embed { position: absolute; top: 0; left: 0; width: 100%; height: 100%; }<\/style><div class=\"embed-container\"><iframe src=\"https:\/\/www.youtube.com\/embed\/\/8PEzmFMvjPY\" frameborder=\"0\" allowfullscreen=\"\"><\/iframe><\/div>\n\n\n\n<div style=\"height:63px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>El CRG i l&#8217;empresa d&#8217;identificaci\u00f3 de f\u00e0rmacs Chemotargets, una spin-off de l&#8217;IMIM, han unit forces per afavorir el desenvolupament de noves ter\u00e0pies per a diferents malalties, com el c\u00e0ncer o la fibrosi.<\/p>\n","protected":false},"author":9,"featured_media":26440,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[26],"tags":[261,265,629,271,233],"new-type":[35],"class_list":["post-26462","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-recerca","tag-bioinformatica","tag-crg-ca","tag-desenvolupament-de-farmacs","tag-divisio-cellular","tag-farmacologia","new-type-noticies"],"acf":[],"_links":{"self":[{"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/posts\/26462","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/comments?post=26462"}],"version-history":[{"count":6,"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/posts\/26462\/revisions"}],"predecessor-version":[{"id":26519,"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/posts\/26462\/revisions\/26519"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/media\/26440"}],"wp:attachment":[{"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/media?parent=26462"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/categories?post=26462"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/tags?post=26462"},{"taxonomy":"new-type","embeddable":true,"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/new-type?post=26462"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}